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Abstract
Background: Abnormal distribution, modification and aggregation of transactivation response DNA-binding
protein 43 (TDP-43) are the hallmarks of multiple neurodegenerative diseases, especially frontotemporal lobar
degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS). Researchers have
identified 44 mutations in the TARDBP gene that encode TDP-43 as causative for cases of sporadic and familial ALS
http://www.molgen.ua.ac.be/FTDMutations/. Certain mutant forms of TDP-43, such as M337V, are associated with
increased low molecular weight (LMW) fragments compared to wild-type (WT) TDP-43 and cause neuronal
apoptosis and developmental delay in chick embryos. Such findings support a direct link between altered TDP-43
function and neurodegeneration.
Results: To explore the pathogenic properties of the M337V mutation, we generated and characterized two mouse
lines expressing human TDP-43 (hTDP-43M337V) carrying this mutation. hTDP-43M337V was expressed primarily in the
nuclei of neurons in the brain and spinal cord, and intranuclear and cytoplasmic phosphorylated TDP-43 aggregates
were frequently detected. The levels of TDP-43 LMW products of ~25 kDa and ~35 kDa species were also increased in
the transgenic mice. Moreover, overexpression of hTDP-43M337V dramatically down regulated the levels of mouse TDP-
43 (mTDP-43) protein and RNA, indicating TDP-43 levels are tightly controlled in mammalian systems. TDP-43M337V mice
displayed reactive gliosis, widespread ubiquitination, chromatolysis, gait abnormalities, and early lethality. Abnormal
cytoplasmic mitochondrial aggregates and abnormal phosphorylated tau were also detected in the mice.
Conclusion: Our novel TDP-43M337V mouse model indicates that overexpression of hTDP-43M337V alone is toxic in
vivo. Because overexpression of hTDP-43 in wild-type TDP-43 and TDP-43M337V mouse models produces similar
phenotypes, the mechanisms causing pathogenesis in the mutant model remain unknown. However, our results
suggest that overexpression of the hTDP-43M337V can cause neuronal dysfunction due to its effect on a number of
cell organelles and proteins, such as mitochondria and TDP-43, that are critical for neuronal activity. The mutant
model will serve as a valuable tool in the development of future studies designed to uncover pathways associated
with TDP-43 neurotoxicity and the precise roles TDP-43 RNA targets play in neurodegeneration.
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Background
TDP-43 is the major component of ubiquitinated inclu-
sions in most cases of ALS and FTLD-U [1,2], and the
link between TDP-43 mutations and neurodegeneration
was first established in 2008 [3,4]. Autosomal dominant
mutations in TARDBP, the gene encoding TDP-43, are
associated with sporadic and familial ALS [3-7]. TDP-43
is a ubiquitously expressed 414-amino acid nuclear pro-
tein and a highly conserved heterogeneous nuclear ribo-
nucleoprotein (hnRNP). TDP-43 has high-binding
affinity for the (TG)n motif and is involved in gene tran-
scription, pre-mRNA splicing, mRNA stability, and
mRNA transport [8,9]. Under disease conditions, TDP-
43 is truncated, phosphorylated, ubiquitinated and
aggregated both in the nucleus and cytoplasm. Under
such conditions, cytoplasmic TDP-43 aggregation
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manner through which TDP-43 causes neurodegenera-
tion has not been identified; however, recently TDP-43
mouse models generated by our group and others
demonstrate that overexpression of TDP-43 [either
wild-type, A315T mutant, G348C or ΔNLS (defective
nuclear localization signal TDP-43)] is toxic and can
cause neurodegeneration in the central nervous system
[10-16]. That being said, the various TDP-43 transgenic
models exhibit other similarities as well as differences.
For instance, most transgenic models showed increased
ubiquitin levels, TDP-43 fragmentation, phosphorylation,
gliosis, motor functional impairments, and shortened
lifespan. On the other hand, neuronal loss, caspase acti-
vation, redistribution of TDP-43 from nuclei to cyto-
plasm, cytoplasmic TDP-43 inclusions, down regulation
of endogenous mTDP-43 and abnormal mitochondrial
aggregation were either only seen in some of those
TDP-43 transgenic mice, or not examined. To further
confirm the toxic effect of TDP-43 overexpression and
to specifically study mutant TDP-43, we generated
transgenic mice expressing hTDP-43M337V under control
of the mouse prion (PrP) promoter [17].
In the TDP-43M337V mice, hTDP-43M337V is mainly
expressed in the brain and spinal cord, a finding that is
consistent with transgenic mice overexpressing wild-
type TDP-43 that we previously reported [11]. TDP-
43M337V mice exhibited certain features similar to those
seen in ALS, such as TDP-43 cleavage, phosphorylation,
aggregation, increased ubiquitination, gliosis, gait distur-
bances, and early lethality; however, the mice also exhib-
ited other features not yet reported in humans, which
may be due to the effect of hTDP-43M337V overexpres-
sion. Such features include: down regulation of mTDP-
43, abnormal mitochondrial aggregation and abnormal
tau phosphorylation.
Results
Generation of transgenic mice overexpressing hTDP-43
M337V protein
To explore the pathogenic properties of mutant
(M337V) TDP-43, we generated transgenic mice using
the mouse prion promoter to constitutively drive
expression of full-length hTDP-43 carrying the M337V
mutation. Three (Lines 1, 4, and 6) of eight independent
founder lines showed germline transmission. The
expression level of human TDP-43 was low in line 1
(~20% of endogenous levels), while lines 4 and line 6
had similar hTDP-43 expression levels to that of wild-
type TDP-43 mice (TDP-43WT line 3c hereafter termed
TDP-43WT), which we previously generated with the
same promoter [11] (Figure 1A, B). Biochemical analyses
of hTDP-43M337V showed that protein expression was
highest in the brain and spinal cord, with low levels in
other tissues (Figure 1C). The immunohistochemistry
(IHC) of hemizygous mice showed that hTDP-43 M337V
expression was primarily in nuclei and distributed
throughout the gray matter of the spinal cord and brain
(Figure 1D, E). Hemizygous mice from all lines were
phenotypically, histologically, and immunohistochemi-
cally indistinguishable from NT mice up to 12 months
of age, currently the oldest age available. Given the simi-
lar levels of expression between lines 4 and 6, the full
characterization of line 4 is shown and all subsequent
description of TDP-43M337V mice refer to homozygous
mice from line 4 unless otherwise noted. The expression
level of hTDP-43M337V in the brains of homozygous
mice was about 1.9 ± 0.06 fold over that of hemizygous
mice (Figure 2A, B). The total levels of TDP-43 protein
(human and mouse TDP-43) in the brains of hemizy-
gous and homozygous mice were 1.6 ± 0.03 and 2.7 ±
0.08 fold that of endogenous mouse TDP-43 in the non-
transgenic mice (NT), respectively (Figure 2A, C). These
results obtained from hTDP-43M337V compared with
total TDP-43 indicated that endogenous mTDP-43 pro-
tein levels were likely down regulated in TDP-43M337V
mice, in a dose-dependent fashion. We confirmed that
mTDP-43 was similarly down regulated at the mRNA
level (~ 20% and 30% reduction of mTDP-43, respec-
tively, compared to NT mice) using real time-PCR ana-
l y s e so fh e m i z y g o u sa n dh o m o z y g o u sb r a i n s( F i g u r e
2D). The mRNA levels of hTDP-43 in the brain of
homozygous mice were 1.86 ± 0.14 fold of that in the
hemizygous mice (Figure 2E), consistent with the
hTDP-43 protein levels. Moreover, the ~25 kDa and
~35 kDa TDP-43 LMW species also increased signifi-
cantly in the hemizygous and homozygous mice, and
their levels correlated with the levels of full-length TDP-
43 (Figure 2F, G).
At approximately post-natal day 21, homozygous
TDP-43M337V mice began to have body tremors and dif-
ficulty recruiting their hindlimbs (not shown). They
failed to show proper escape extension by splaying their
hindlimbs upon elevation, as shown by their NT coun-
terparts (Figure 3A, B). They displayed an irregular,
dragging gait pattern, due at least in part to limb weak-
ness (Figure 3C, D). By ~ 1 month old, homozygous
TDP-43M337V mice had significantly lower brain and
body weight compared with their NT and hemizygous
littermates (Figure 3E, F). Due in part to muscle weak-
ness, homozygous TDP-43M337V mice were unable to
feed from a food hopper, lost the ability to right them-
selves, became moribund and required euthanasia.
Approximately 70% of the homozygous TDP-43M337V
mice became moribund by 1 month of age, which was
statistically significant compared with NT and hemizy-
gous littermates (Figure 3G). We had previous success
(unpublished) extending the lifespan of mouse models
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care such as delayed weaning and supplementing diets
with gel and dough. We have now employed similar
measures in an effort to prolong the lives of homozy-
gous TDP-43M337V transgenic mice. The phenotype of
the homozygous TDP-43M337V mice from line 6 (not
shown) was similar to that described for line 4.
Pathological alteration of TDP-43
Immunohistochemistry was performed on both line 4
and line 6 of TDP-43M337V and NT mice. The results
showed that TDP-43 was mostly in nuclei in the brain
and spinal cord of TDP-43M337V and NT mice and that
the TDP-43M337V mice specifically expressed high levels
of hTDP-43 that were not seen in the controls (Figure
4A-C). Cytoplasmic TDP-43 was detected with either a
human TDP-43 specific antibody or total TDP-43
antibody that recognized both human and mouse TDP-
43. Cytoplasmic TDP-43 was detected in spinal cord
neurons and less frequently in the brainstem and cortex
of TDP-43M337V mice (Figure 4A, B, D and 4E arrow-
head, Table 1). Abnormally phosphorylated (pS403/
pS404) TDP-43 (pTDP-43) was frequently located
within nuclear bodies or diffusely within the cytoplasm
of motor neurons in the anterior horns of the spinal
cord of TDP-43M337V mice (Figure 4G, H arrowheads,
arrows) but not in the NT mice (Figure 4I). Far less
cytoplasmic pTDP-43 was detected in the posterior
horn of TDP-43M337V mice and in the brainstem (< 5
neurons/section; Table 1). pTDP-43-immunoreactive
nuclear bodies were not detected in the brains of TDP-
43M337V mice (Table 1). Multiple small, distinct, cyto-
plasmic inclusions that were immunoreactive for pTDP-
43 were frequently observed within neurons in layer V
Figure 1 TDP-43 expression in TDP-43 M337V mice. (A) Western blots of brain lysates from non-transgenic (NT) mice, founder line 1, 4, 6 of
TDP-43M337V hemizygous mice and line 3c of TDP-43WT hemizygous mice show that TDP-43M337V (lines 4, 6) and TDP-43WT mice are expression
matched for both total (mTDP-43 and hTDP-43) and hTDP-43 levels, which was subsequently confirmed (B) by densitometric measurements.
Compared with NT mice (1 ± 0.04), the levels of total TDP-43 in lines 1, 4, 6 and 3c are 1.2 ± 0.05; 1.6 ± 0.07; 1.3 ± 0.17; 1.9 ± 0.22 fold
respectively. Compared to line 1(1 ± 0.06), the levels of hTDP-43 of line 4, 6 and 3c are 8.3 ± 1.2; 7.7 ± 1.0 and 8.3 ± 1.3 fold, respectively. Data
shown in (B) are means ± SEM of six different mice of each genotype. (C) Western blot of tissue lysates of TDP-43 M337V mice from brain (Br),
spinal cord (SC), thigh muscle (TM), heart (He), stomach (St), kidney (Ki), live (Li) and spleen (Sp) probed with an antibody against hTDP-43
reveals high expression in the brain and spinal cord (line 4). (D-E) Immunohistochemistry shows hTDP-43 distributed throughout the gray matter
of the spinal cord (A) and brain (B) in the hemizygous TDP-43M337V mice.
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a r r o w s )t h a tw e r en o to b s e r v ed in NT controls (Figure
4L). The extent and distribution of these features in the
TDP-43M337V mice was similar to that observed in our
previously reported TDP-43WT mice [11].
Cytoplasmic eosinophilic aggregates, ubiquitination, and
gliosis in TDP-43M337V mice
A striking histological feature in TDP-43M337V mice was
the presence of cytoplasmic eosinophilic aggregates (Fig-
ure 5A) located within the neurons of the anterior horn
of the spinal cord and less frequently in the posterior
horn and brainstem. These aggregates were absent from
NT mice (Figure 5B). Neuronal loss due to apoptosis
was not detected in TDP-43M337V mice, as assessed by
TUNEL staining and staining for activated caspase 3
(data not shown); however, increased ubiquitination and
reactive gliosis were observed in TDP-43M337V mice and
not in NT mice (Figure 5C-J). Ubiquitination was both
widespread, and generally increased, in both the nucleus
and cytoplasm of neurons in spinal cord and brain (Fig-
ure 5C, E). Ubiquitination was more widespread than
cytoplasmic TDP-43 or phospho-TDP-43 aggregates
(Table 1), and co-immunoprecipitation studies indicated
that hTDP-43 was not ubiquitinated (Additional file 1).
Reactive gliosis was also seen in the TDP-43M337V mice,
as GFAP-positive astrocytes and IBA-1-positive micro-
glia were elevated in the spinal cord and brainstem of
TDP-43M337V mice compared with NT mice (Figure 5G-
J; Table 1). Each of these features observed in the TDP-
43M337V mice was similar to that observed in our pre-
viously reported TDP-43WT model [11]. Homozygous
TDP-43M337V mice from line 4 and 6 (not shown)
showed similar pathological changes.
Abnormal mitochondrial aggregates in TDP-43M337V mice
The eosinophilic aggregates in spinal motor neurons of
TDP-43M337V mice were immunoreactive for the mito-
chondrial marker, COX-IV (Figure 6A), which indicates
the aggregates were composed of abnormal clusters of
Figure 2 Down regulation of mouse TDP-43 and production of lower molecular weight (LMW) TDP-43 species in TDP-43M337V mice.
Western blots (A) of brain lysates from NT, hemizygous (Hemi) and homozygous (Homo) TDP-43M337V mice probed for hTDP-43 or total TDP-43
levels were quantified by (B) densitometry to show that mutant hTDP-43 expression is approximately 90% higher in homozygous mice
compared to hemizygous mice (Hemi = 1 ± 0.04; Homo = 1.9 ± 0.06), ** p < 0.001. Densitometric analysis (C) shows that total TDP-43 levels in
each genotype group (NT = 1 ± 0.05; Hemi = 1.6 ± 0.03; Homo = 2.7 ± 0.08). ** p < 0.001. Data shown are means ± SEM of six different mice
of each genotype. (D) Quantitative real time PCR (qPCR) using mTDP-43-specific primers demonstrate the mRNA levels of mTDP-43 in NT,
hemizygous and homozygous mice brain (NT = 1 ± 0.07; Hemi = 0.8 ± 0.05; Homo = 0.7 ± 0.01). * p < 0.05, ** p < 0.01. (E) qPCR using hTDP-43
- specific primers shows the mRNA levels of hTDP-43 in hemizygous and homozygous mice brain (Hemi = 1 ± 0.09; Homo = 1.86 ± 0.14). ** p <
0.01. Data shown in (D) and (E) are means ± SEM of four different mice of each genotype. (F) Darker exposure of the Western blot shown in (A)
revealed increased LMW species of TDP-43 in hemi- and homozygous TDP-43M337V mice. (G) Densitometric analysis of ~25 kDa and ~35 kDa
TDP-43 species indicates that both species correlate with total TDP-43 expression (For ~25 kDa species, NT = 1 ± 0.14; Hemi = 1.4 ± 0.21; Homo
= 3.4 ± 0.26. For ~35 kDa species, NT = 1 ± 0.32; Hemi = 1.6 ± 0.28; Homo = 2.4 ± 0.13). ** p < 0.01. Data shown are means ± SEM of six
different mice of each genotype.
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redistribution of COX-IV immunostaining into the jux-
tanuclear pattern observed in the TDP-43M337V mice.
Electron microscopic (EM) results confirmed that the
majority of neuronal cytoplasmic inclusions in the spinal
motor neurons of TDP-43M337V mice contained aggre-
gates of mitochondria (Figure 6C) that were occasionally
surrounded by a core of microtubules (20 nm) in ran-
dom orientations (Figure 6D). The aggregated mito-
chondria showed variable degrees of loss of inner cristae
Figure 3 Reduced brain and body weight and motor dysfunction in TDP-43M337V mice. (A-B) Upon tail elevation, NT mice (A) showed normal
escape response by splaying their hind limbs while homozygous TDP-43M337V mice (B) held their hind limbs close to their body and failed to show
proper escape extension. (C-D) Gait of NT and TDP-43M337V mice was evaluated by inked foot placement on paper. 1 month old (C) NT mice show
normal foot placement and gait; whereas, (D) homozygous TDP-43M337V mice showed an irregular, inwardly-placed foot falls with a dragging
pattern. Forepaws and hind paws were coated in red and blue ink, respectively, to evaluate placement of paws during travel. (E) At 1 month, brain
weight and (F) body weight of homozygous TDP-43M337V mice was significantly lower than that of age-matched NT and hemizygous mice. Brain
weight: NT = 428 ± 9 mg; Hemi = 429 ± 11 mg; Homo = 338 ± 29 mg. Body weight: NT = 12.3 ± 1 g; Hemi = 12 ± 2 g; Homo = 6 ± 2 g. Data
shown are the means ± SEM of 6-8 mice per group. ***p < 0.0001. (G) Hemizygous TDP-43M337V mice were mated, and the survival of the resulting
pups of each genotype was determined. The results are plotted as a percentage of pups alive per postnatal day of life. Survival rate for all cohorts
were calculated using Kaplan-Meier methods (p < 0.001 for overall log-rank test). Homozygous TDP-43M337V mice had higher mortality (about 70%
death) around 1 month of age, which was statistically significant compared with NT and hemizygous littermates (p < 0.001).
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Page 5 of 14Figure 4 Distribution of TDP-43 and phosphorylated TDP-43 (pTDP-43) aggregates in TDP-43M337V mice. Immunostaining in spinal cord
sections of a 1-month old TDP-43M337V from (A) line 4, (B) line 6 and (C) NT mice shows hTDP-43 in nuclei, with occasional cytoplasmic staining
(arrowhead); hTDP-43 was not observed in NT mice. (D-F) Immunostaining of spinal cord sections for total TDP-43 shows that TDP-43
immunoreactivity in both nuclei and cytoplasm in TDP-43M337V mice (arrowhead) (D-E), but only in nuclei in NT mice (F). Immunostaining of
spinal cord (G-I) or cortical (J-L) neurons for phosphorylated (p403/404) TDP-43. (G-H) Nuclear bodies (arrowheads) within spinal motor neurons
of TDP-43M337V mice immunostained for pTDP-43. Occasionally, diffuse cytoplasmic pTDP-43 was found within the motor neurons in the anterior
horn of TDP-43M337V mice (arrows). (I) NT mice lacked similar pTDP-43 staining in the spinal cord. (J-K) Cytoplasmic aggregates of pTDP-43
(arrows) were often seen in cortical neurons of TDP-43M337V mice that were absent from (L) NT mice. Scale bars: 50 μM.
Table 1 Regional distribution of pathologies in TDP-43M337V mice
Cortex, layer
V
Hippocampus Striatum Brainstem Cerebellum Anterior horn of spinal
cord
Posterior horn of spinal
cord
Cytoplasmic TDP-43 + - - + - ++ +
Nuclear pTDP-43 - - - +/- - ++ +
Cytoplasmic pTDP-43 ++ - - + - ++ +
Ubiquitination ++ + + ++ - ++ ++
IBA-1-positive
microglia
+ - - ++ - ++ +
GFAP-positive
astrocytes
+ - - ++ - ++ +
Mitochondrial
aggregates
+- - + - + + +
p-tau ++ ++ + + - +/- +/-
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chondria in TDP-43M337V mice (Figure 6E) were smaller
than those in NT mice (Figure 6F). In NT mice, mito-
chondria were usually admixed with other cytoplasmic
organelles such as endoplasmic reticulum and ribosome
(Figure 6F); however, this intervening organelles were
absent in the neuronal aggregates of TDP-43M337V mice
(Figure 6E). The mitochondrial aggregates in the TDP-
43M337V mice were frequent in the spinal cord and
brainstem, less frequent in the cortex, and rare in other
brain regions (Table 1). Homozygous TDP-43M337V
mice from line 6 also developed juxtanuclear mitochon-
drial aggregates (not shown).
M337V TDP-43 does not alter mitochondrial fusion and
fission proteins
We have previously demonstrated that mitochondrial
clustering in neurons of TDP-43WT mice is accompa-
nied by changes in protein levels and/or phosphoryla-
tion of proteins that regulate mitochondrial fission and
fusion [11]. Given the similarity between mitochondrial
aggregates in TDP-43M337V mice and our previously
described TDPWT mice, we sought to determine if mito-
chondrial fission and fusion proteins were altered in the
TDP-43M337V mice. Surprisingly, the alterations to
pDLP1 (Ser616), Fis1, and MFN1 that were observed in
the TDP-43WT mice, regardless of line, were not present
in the TDP-43M337V mice, despite the comparable mito-
chondrial aggregation in each transgenic model (Addi-
tional file 2).
Chromatolysis in TDP-43M337V mice
In the spinal motor neuron of TDP-43M337V mice, Nissl
bodies became dispersed (Figure 7A) compared to NT
mice (Figure 7B). There was disintegration of chromophil
substance primarily within the cell bodies of the spinal
cords of TDP-43M337V mice (Figure 7C) that was not
observed in NT mice (Figure 7D). Ultrastructural analysis
showed reduced cytoplasmic density and less cytoplasmic
organelles in TDP-43M337V mice (Figure 7E) compared to
NT mice (Figure 7F). These finding are indicative of chro-
matolysis and suggest that neurons in TDP-43M337V mice
are undergoing perikaryal response to axonal degeneration.
Hyperphosphorylated tau accumulation in TDP-43M337V
and TDP-43WT mice
Abnormal, phosphorylated tau was found in the brains
of both TDP-43WT and TDP-43M337V mice. Immunohis-
tochemical analyses of the cortices of TDP-43M337V (Fig-
ure 8A) and TDP-43WT mice (Figure 8B) showed
significantly elevated phosphorylated tau (CP13) immu-
noreactivity throughout the neuropil of the brain com-
pared with NT mice (Figure 8C). Additionally,
cytoplasmic tau accumulations were found in the TDP-
43WT mice and much less frequently in the TDP-
43M337V mice (Figure 8A, B). Western blots of brain
lysates showed that the levels of phosphorylated tau
(CP13) were significantly increased in both the TDP-
43WT and TDP-43M337V mice (Figure 8D), while the
level of dephosphorylated tau (Tau-1) was dramatically
decreased. There was no significant change in the level
Figure 5 Neuropathology in TDP-43M337V mice. Hematoxylin and eosin staining revealed (A, arrows) eosinophilic aggregates in spinal motor
neurons from TDP-43M337V mice that are not observed in (B) NT mice. Abnormal ubiquitin immunoreactivity was present in the cytoplasm and
nucleus of neurons in the (C) spinal cord of TDP-43M337V mice, but not in (D) NT mice. Similar ubiquitination was observed in the (E) cortex of
TDP-43M337V mice, but not in (F) NT mice. Enhanced (G-H) GFAP and (I-J) IBA-1 immunoreactivity indicative of reactive astrogliosis and activated
microglia, respectively, were observed in TDP-43M337V mice (G, I), but not NT mice (H, J). Scale bars: 100 μM.
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mechanism for tau phosphorylation, we examined pro-
tein kinases and phosphatases and found significant
increases in phospho-(Ser) PKC substrate in both TDP-
43WT and TDP-43M337V mice, indicating PKC activation
may be responsible for such abnormal tau phosphoryla-
tion (Figure 8D). The levels of other tau kinases, such as
GSK-3b and CDK5, and the tau phosphatase PP2A were
not significantly changed in the TDP-43M337V and TDP-
43WT mice (data not shown). Abnormally phosphory-
lated tau was rarely found in the spinal cord (data not
shown). The regional distribution of hyperphosphory-
lated tau is summarized in Table 1.
Discussion
In the current study, we generated and characterized a
novel transgenic mouse model that overexpresses
hTDP-43 carrying the M337V mutation under the
mouse prion promoter. Homozygous TDP-43 M337V
mice (referred to as TDP-43M337V mice) develop pheno-
typic and pathologic features including gait disturbances,
gliosis, increased ubiquitination, TDP-43 truncation,
phosphorylation, and both nuclear and cytoplasmic
phosphorylated inclusions.
Importantly, the novel findings described in the cur-
rent manuscript and the counterpart TDP-43WT mice
manuscript [11], demonstrate expression of human
TDP-43 at similar levels results in remarkably similar
phenotypes and pathologies, suggesting that the pheno-
types of both models are due to TDP-43 overexpression,
and not specifically due to this mutation. Previously
published findings regarding TDP-43 overexpression in
mouse models strongly suggested that overexpression of
TDP-43 itself is toxic; however, none of these studies
Figure 6 Abnormal mitochondrial aggregations in TDP-43M337V mice. COX-IV immunoreactivity illustrates densely stained aggregates in a
spinal motor neuron of (A) TDP-43M337V mice, but not in (B) NT mice. (C) Electron micrograph of a spinal motor neuron from a TDP-43M337V
mouse shows a cluster of mitochondria surrounding a filamentous core (boxed area). (D) Enlargement of the filamentous core showing 20 nm
filaments and various vesicles. Small dense granules are stain precipitates. (E) Electron micrograph of a mitochondrial aggregate in another spinal
motor neuron of the TDP-43M337V mouse. Note the close proximity of mitochondria with varying degrees of degenerating inner cristae
(arrowheads), compared to normal mitochondria in motor neurons of (F) NT mice. (E) The degenerating mitochondria of TDP-43M337V mice also
appear smaller in size compared with those of (F) NT mice. Asterisk in (E) indicates a vacuolated mitochondrion. (F) In NT mice, mitochondria
(arrows) were usually separated by other cytoplasmic organelles, e.g. rough endoplasmic reticulum (arrowheads) and ribosomes. Scale bars: 50
μM in A and B.
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Page 8 of 14Figure 7 Chromatolysis in TDP-43M337V mice. Nissl staining of motor neurons of (A) TDP-43M337V mice is much weaker than that in (B) NT
mice. (C) Electron micrograph of a chromatolytic neuron of TDP-43M337V mice compared to the (D) normal neuron of the NT mouse shows
rarefaction of cytoplasmic organelles (E), compared with the normal cytoplasmic density (D) and packed organelles (F) of NT mice. Scale bars: 20
μM in A and B; 5 μM in C and D; and 1 μM in E and F.
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able in expression level and pattern, promoter system,
and strain to WT TDP-43 counterparts [10-16]. In con-
stitutive transgenic rat studies, Zhou and colleagues
reported that mutant M337V TDP-43 appeared to be
more toxic than wild-type TDP-43 [18] even though the
animals expressed the hTDP-43 protein at similar levels.
It is unclear why there is a discrepancy between our
mutant and wild-type TDP-43 transgenic models and
those in the rat. One possibility could be the difference
of promoters utilized in the studies. Additionally, Zhou
and colleagues did not look at endogenous rat TDP-43
levels in response to the hTDP-43 overexpression [18];
therefore, it is possible that differences in endogenous
TDP-43 played a role in the rat phenotype. Moreover,
in contrast to our hTDP-43 cDNA construct, the consti-
tutive hTDP-43 construct utilized by Zhou and collea-
gues is a hTDP-43 minigene [18], which appears to
contain 3’UTR and binding regions that have been
shown recently to be required for autoregulation of
TDP-43 [19,20]. Given this, it is possible that the hTDP-
43 in the constitutive rat model is also autoregulated
and that the presence of the mutation in the hTDP-43
minigene prevents autoregulation of the mutant, but not
the wild-type, hTDP-43. Finally, in the TDP-43 rat mod-
els, there appears to be extensive hTDP-43
Figure 8 Tau pathology in TDP-43M337V mice. Immunohistochemistry of the cortices of (A) TDP-43M337V and (B) TDP-43WT mice showed
elevated levels of phosphorylated tau (CP13) in both TDP-43M337V and TDP-43WT mice compared to (C) NT mice. (D) Western blotting of brain
lysates from NT, TDP-43 M337V and TDP-43WT mice probed with CP13 antibody showed increases in murine tau phosphorylation at serine
residues 202 in both lines of TDP-43 transgenic mice. Staining with tau-1 antibody showed reduced dephosphorylated tau levels in both lines of
TDP-43 transgenic mice when compared to NT mice. Staining with antibody tau-5 showed that overall tau levels were equivalent across non-
transgenic and transgenic mice. There was a dramatic increase of phospho-(Ser) PKC substrate in both TDP-43 transgenic lines indicating PKC
activation that was not present in NT mice. Scale bars: 50 μM in A, B and C.
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Page 10 of 14immunoreactivity in both the nucleus and the cyto-
plasm, regardless of mutation; whereas, TDP-43 mainly
localized in the nuclei in both of our TDP-43M337V and
TDP-43WT mice. The toxicity that we observe in our
TDP-43 transgenic mice is therefore likely to be due, at
least in part, to the impact of high TDP-43 levels on
nuclear functions. Overexpression of TDP-43 in the
nuclei of TDP-43 mice may interfere with interaction
with its DNA and RNA targets, disrupt normal substrate
metabolism and lead to neuronal dysfunction. Recent
efforts to identify neuronal RNA targets of TDP-43
implicated in neurodegeneration led to the identification
of FUS/TLS, progranulin, tau and ataxin1 and -2 and
TDP-43 itself [20-22]. Additional studies are needed to
explore the precise roles of TDP-43 DNA/RNA targets
at work in these mouse models. Both TDP-43 LMW
species and cytoplasmic TDP-43 are present in our
TDP-43 mice, and they may also contribute to the
pathologies and abnormal behavior.
Our results showed that overexpression of hTDP-
43M337V can down regulate endogenous mouse TDP-43
levels, which is consistent with the property of TDP-43
autoregulation. TDP-43 can autoregulate its mRNA
level, in part by directly binding to the 3’UTR of its own
transcript, thereby triggering exosome-mediated degra-
dation or nonsense-mediated RNA degradation [19,20].
The C-terminal region (a.a 321-366) of TDP-43 is
required for autoregulation [19]. Recent reports allow
for the possibility that mutation of TDP-43 within the
C-terminus may affect the efficiency of autoregulation;
however, the presence of the M337V mutant within
hTDP-43 did not impair its ability to regulate endogen-
ous mTDP-43. The loss of nuclear mTDP-43 in
response to hTDP-43M337V overexpression has been
proposed to play a role in the pathogenesis observed in
another TDP-43 transgenic mouse model [14]. Consid-
ering the substantial homology between the hTDP-
43M337V and mTDP-43 proteins, it would seem likely
that hTDP-43M337V might functionally compensate for
t h el o s so fm T D P - 4 3 ,b u tw ec a n n o te x c l u d et h ep o s s i -
bility that loss of nuclear mTDP-43 may contribute to
the phenotype of hTDP-43M337V transgenic mice.
Abnormal mitochondrial accumulation has now been
observed in both our TDP-43M337V and TDP-43WT mice
[11] and in another wild-type TDP-43 overexpressing
mouse model driven by Thy1.2 promoter [13], suggest-
ing that TDP-43 can regulate mitochondrial dynamics.
In addition to clustering of mitochondria, the size and
the ultrastructural integrity of neuronal mitochondria
was reduced in our TDP-43 mice compared with mito-
chondria of NT mice. In the TDP-43WT mice, we had
previously identified changes in levels and the phosphor-
ylation state for proteins that critically regulate mito-
chondrial fission and fusion and suggested that these
changes may contribute to the abnormal aggregation
and morphology of mitochondria. Surprisingly, we did
not find similar changes in mitochondrial fission and
fusion proteins in the TDP-43M337V mice, suggesting
that mitochondrial aggregation observed in both TDP-
43 models may result from another pathogenic pro-
cesses, such as axonal degeneration.
On occasion, mitochondrial clusters within the neurons
of the TDP-43M337V mice were associated with microtu-
bules. TDP-43 may alter the microtubule-based mitochon-
drial transportation system and lead to both microtubule
and mitochondrial aggregation and dysfunction. While
there are a number of ways through which this could
occur, it was interesting to find that the microtubule asso-
ciated protein tau was abnormally hyperphosphorylated in
the brain of both our TDP-43WT and TDP-43M337V mice.
Tau functions to stabilize microtubules and to facilitate
axonal transport. Abnormal phosphorylation of tau can
reduce its ability to bind microtubules [23]. A number of
kinases can phosphorylate tau, and one of these kinases,
PKC, was activated in both TDP-43M337V and TDP-43WT
mice. Tau hyperphosphorylation might be partially due to
PKC activation in the mice; however, the paradigm
through which TDP-43 overexpression resulted in tau
hyperphosphorylation and/or PKC activation is still
unclear. One possibility is that exacerbated TDP-43 auto-
regulation disrupts the homeostasis of other key proteins
and eventually leads to dysfunction. Alternatively, PKC
activation and tau hyperphosphorylation could be second-
ary or unrelated to mitochondrial clustering. There is a
large body of evidence suggesting that axonal transport is
disrupted in ALS [24,25], which includes evidence that
SOD1 mutations impair axonal transport [26,27]. Interest-
ingly, depletion of kinesin heavy chain (kif5B) results in
mitochondrial perinuclear clusters similar to those
described in our TDP-43 models [28].
One limitation of our model is that although many of
the features are consistent with those observed in ALS,
there are several features of this model that are incon-
gruous with the human disease. Phenotypically, our
mice show retarded growth from early life; whereas,
humans with ALS typically show progressive disease
after initially normal development into adulthood. While
our TDP-43M337V mice show early lethality, the age at
death for the mice is significantly younger in compari-
son to the lifespan of humans with ALS due to muta-
tions in TDP-43. We did not see loss of nuclear TDP-43
immunoreactivity similar to that observed in affected
neurons in ALS, even in cells with cytoplasmic TDP-43
inclusions. It is possible that mTDP-43 underwent redis-
tribution as recently reported in another TDP-43 mouse
model [14]; however, we are unable to confirm this due
to unavailability of mTDP-43-specific antibody. We also
observed considerable chromatolysis in the TDP-
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end stage human ALS, and often only detected in cases
with rapid disease progression [29]. TDP-43M337V mice
also exhibit other pathologies not frequently seen in
humans, such as abnormal mitochondrial aggregation.
Interestingly, increased phospho-tau has been reported
in ALS patients, especially those with cognitive impair-
ment [30,31], which suggests that further analysis of a
potential relationship between TDP-43 and tau in
mouse models and in human cases might be warranted.
The motor, biochemical, and pathological features
observed in TDP-43M337V mice (line 4) were also noted
in a second independent line of TDP-43M337V mice (line
6), suggesting that these features were not simply due to
transgene insertional effects.
We observed some regional differences in our TDP-43
transgenic models, despite the relatively uniform expres-
sion of the TDP-43 proteins throughout the gray matter
of the brain and spinal cord. For example, nuclear pTDP-
43 inclusions, abnormal mitochondrial aggregation and
chromatolysis were mainly observed in spinal cord, while
cytoplasm pTDP-43 inclusions and tau phosphorylation
were primarily seen in the brain. This indicates that the
mechanisms regulating TDP-43 and being regulated by
TDP-43 are likely to be different in the brain and spinal
cord and warrant further investigation.
Conclusion
In summary, this novel TDP-43M337V mouse model indi-
cates that overexpression of hTDP-43M337V alone is toxic
in vivo.T D P - 4 3 M337V mice recapitulate certain patholo-
gic features seen in neurodegenerative diseases, including
TDP-43 fragmentation, phosphorylation, aggregation,
increased ubiquitination and gliosis. While these features
could also indicate general neuronal dysfunction, the
mice also exhibit down regulation of mouse TDP-43,
abnormal mitochondria aggregation and abnormal tau
phosphorylation. Because overexpression of mutant
hTDP-43 produces phenotypes similar to the wild-type
TDP-43 model, the mechanisms causing pathogenesis in
the mutant model remain unknown. However, these
results should not be surprising, given the mutant TDP-
43 and wild-type TDP-43 biochemically are similar in
human disease. As such, the TDP-43M337V mice may
serve as a valuable tool for future studies of yet-to-be-
examined disease pathways and the precise roles TDP-43
RNA targets play in neurodegeneration.
Methods
Generation of TDP-43M337V Transgenic Mice
The human wild-type TDP-43 cDNA was generated as
previously described [11] and was inserted into the XhoI
site of the pcDNA 3.1. To generate the M337V muta-
tion, site directed mutagenesis was performed using
Quikchange kit (Strategene). The primers used for the
mutation were: 5’-CAGTTGGGGTATGGTGGG-
CATGTTAGC-3’ and 5’-GCTAACATGCCCACCA-
TACCCCAACTG-3’. After confirming the mutation by
sequencing, the M337V TDP-43 cDNA was inserted
into the XhoI site of MoPrP vector [17]. Following
sequencing, the construct was linearized with NotI, gel
purified and digested with b-agarose. DNA was filtered,
concentrated and diluted to 3 ng/μl in microinjection
buffer. The transgene was microinjected into fertilized
C57BL/6 (B6) mouse eggs and re-implanted into pseu-
dopregnant females. Eight founders were mated with B6
mice to determine germline transmission and establish
expression levels. TDP-43 founder lines (line 4 and 6)
that have similar transgene levels to the TDP-43WT
mice we previously described [11], were used for all sub-
sequent experiments. Homozygous mice were produced
through a crossbreeding of transgenic mice from the
same line. At no time were lines 4 and 6 intercrossed.
Procedures were performed in accordance with the
Mayo Institutional Animal Care and Use Committee.
Genotyping
Transgenic mice were identified by PCR using hTDP-
43-specific primers: 5’- TGGAGAAGTTCTTATGGTG-
CAGGTC-3’ and 5’-GGTATTAGCCTATGGGGGA-
CAC-3’ against control actin-specific primers (5’-
CGGAACCGCTCATTGCC-3’ and 5’-ACCCA-
CACTGTGCCCATCTA-3’). Homozygous mice were
identified by Quantitative real-time PCR (see Quantita-
tive real-time PCR section).
Quantitative real-time PCR
Levels of human and mouse TDP-43 transcripts were
determined via TaqMan
® Gene Expression Assays
(Applied Biosystems, Carlsbad, CA). Total RNA was iso-
lated either from tail samples for identification of homo-
zygous mice or from brain or spinal cord tissue to
determine the levels of human and mouse TDP-43 tran-
scripts. TRIzol (Invitrogen, Carlsbad, CA) and Pure
Link™ RNA Mini Kit (Invitrogen, Carlsbad, CA) were
used for RNA extraction. 3 μgR N Aw e r eu s e dt o
synthesize cDNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Carls-
bad, CA). The qPCR assay used the following: hTDP-43
Hs00606522_m1, mTDP-43 Mm00523866_m and 18S
rRNA Hs99999901_s1. The PCR was run on the ABI
7900 and data analyzed using Software RQ Manager 1.2
(Applied Biosystems, Carlsbad, CA).
Tissue preparation
Sagittal half brain and spinal column were immersion
fixed in 10% formalin for immunohistochemistry, and
the other half brain was frozen on dry ice for
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removed from the vertebral column and fixed overnight.
Western Blotting
Tissues were homogenized at 10 ml/g (volume/weight) in
lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 1%
Triton X-100, 5 mM EDTA, 2% SDS, PMSF, and pro-
tease and phosphatase inhibitor). Following centrifuga-
tion, supernatant was assessed by BCA assay (Pierce,
Rockford, IL). Following western blotting, membranes
were incubated with mouse monoclonal TDP-43 anti-
body, which was generated using amino acids 1 to 261 of
hTDP-43 as the immunogen and was found to recognize
amino acids 205-222 of hTDP-43 by epitope mapping
[32]; rabbit polyclonal TDP-43 antibody against amino
acids 288-441; mouse CP13; mouse Tau 5; mouse tau-1;
mouse monoclonal glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) antibody; Phospho-(Ser) PKC Substrate
Antibody; mouseDLP1 antibody; rabbit phospho-DLP1
(Ser616) antibody; rabbit Fis1 antibody; or mouse mitofu-
sin 1 antibody. See Additional file 3 for a complete list of
primary antibodies used. Following incubation with an
appropriate secondary antibody, immunoreactivity was
visualized by ECL and exposure to film.
Immunohistochemistry (IHC) and histochemistry
Tissues were embedded in paraffin, sectioned (5 μm thick)
and mounted on glass slides. Sections were deparaffinized
in xylene and rehydrated in a graded series of alcohol, fol-
lowed by dH20. Antigen retrieval was performed in a
dH2O steam bath for 30 min. Tissues were immunos-
tained with monoclonal TDP-43 antibody or antibodies
toward pS403/S404-phosphorylated TDP-43, ubiquitin,
glial fibrillary acidic protein (GFAP), ionized calcium-bind-
ing adaptor molecule 1 (IBA-1), cytochrome oxidase subu-
nit IV (COX-IV), or phospho-tau (CP13; pS202 tau) using
the DAKO Autostainer (Dako Auto Machine Corporation)
and the DAKO EnVision+ HRP system. DAKO Liquid
DAB Substrate-Chromogen system was the chromogen.
See Additional file 3 for a complete list of primary antibo-
dies used. After immunostaining, sections were briefly
counterstained with hematoxylin to stain cell nuclei and
coverslipped. Paraffin-embedded sections were also
stained with hematoxylin and eosin.
Electron Microscopy
Spinal cords from 4%-paraformaldehyde-perfused mice
were immersed in 2.5% glutaraldehyde-0.1 M cacodylate
buffer, post-fixed in 1% OsO4, dehydrated in alcohol
and propylene oxide, and finally infiltrated and
embedded in Epon 812. Ultrathin sections mounted on
copper grids were stained with uranyl acetate and lead
citrate. Images were obtained with a Gatan CCD camera
using a Philips 208S electron microscope.
Gait Analysis Methods
Front paws were painted red, and hind feet were painted
blue with nontoxic paint. The mice were placed in a
plastic tunnel with a strip of white paper covering the
floor. At the end of the tunnel was an enclosed black
box to encourage mice to cross the paper and into the
box. The test was repeated until mice left at least five
pairs of adjacent footprints.
Statistics
One-way ANOVA with Tukey’s posthoc analysis were used
to compare measures among 3 groups. Student’st - t e s ta n a -
lysis was used to compare measures between 2 groups.
Kaplan-Meier methods were used for survival analysis. For
data presentation, normalized values were averaged and
presented as mean ± standard error of means (SEM).
Values of p < 0.05 were considered statistically significant.
Additional material
Additional file 1: Figure A1: Increased ubiquitin levels in TDP-
43M337V mice but hTDP-43 itself is not ubiquitinated. Human TDP-43
was immunoprecipitated from brain homogenates derived from
nontransgenic and homozygous TDP-43m337v mice. Briefly, brain
homogenates containing 500 μg protein were incubated with 1.5 μg
mouse monoclonal TDP-43 antibody overnight at 4°C with gentle
shaking. Protein G agarose was added for 4 h at 4°C then pelleted by
centrifugation. Protein thus captured was eluted using sample loading
buffer and resolved by SDS/PAGE for Western blot analysis. Shown are
immunoblots of the inputs and the immunoprecipitated proteins,
probed using an antibody to ubiquitin or to total TDP-43. Note that a
marked increase in ubiquitin levels is observed in the homogenates
derived from homozygous mice prior to immunoprecipitation.
Nonetheless, the immunoprecipitated human TDP-43 is not
immunopositive for ubiquitin. Arrow = IgG Heavy Chain.
Additional file 2: Figure A2: No mitochondrial fission and fusion
protein changes in TDP-43M337V mice. Immunoblot analysis of Ser616-
phosphorylated DLP1, DLP1, Fis1, and mitofusin 1 (MFN1) expression
level in brain lysates of nontransgenic(NT), hemizygous(Hemi), and
homozygous(Homo) TDP-43M337V mice of both line 4 and line 6. There
are no significant protein changes among different mice groups.
Additional file 3: Additional Table: Primary Antibody List. Full list of
the primary antibodies used in this study.
List of abbreviations
ALS: amyotrophic lateral sclerosis; FTLD-U: frontotemporal lobar
degeneration with ubiquitin-positive inclusions; TDP-43: TAR DNA binding
protein-43; hTDP-43: human TDP-43; mTDP-43: mouse TDP-43. pTDP-43:
phospho-TDP-43.
Acknowledgements
This work was supported by the AFAR Affiliate Research Grant Program (YZ),
Mayo Clinic Foundation (DWD, JL, LP), National Institutes of Health/National
Institute on Aging [5R01AG026251-04 and P01-AG17216-08 (LP)], National
Institutes of Health/National Institute of Neurological Disorders and Stroke
[R01 NS 063964-01 (LP) and 1R21NS071097-01 (JL)], Amyotrophic Lateral
Sclerosis Association (LP, JL) and Department of Defense [USAMRMC
PR080354 (LP, JL) and AL093108 (LP)]. We would like to thank Jimei Tong,
Cindy Yu, Monica Castanedes-Casey, Linda Rousseau and Virginia Phillips for
technical support.
Xu et al. Molecular Neurodegeneration 2011, 6:73
http://www.molecularneurodegeneration.com/content/6/1/73
Page 13 of 14Author details
1Department of Neuroscience, Mayo Clinic, (4500 San Pablo Road),
Jacksonville, (32224), USA.
2Center for Translational Research in
Neurodegenerative Disease (CTRND), College of Medicine, University of
Florida, (1275 Center Drive), Gainesville, (32610), USA.
3Department of
Neuroscience, College of Medicine, University of Florida, (1275 Center Drive),
Gainesville, (32610), USA.
Authors’ contributions
YX and YZ performed experiments, data analysis and co-wrote the
manuscript. XC performed experiments, WL performed Electron Microscopy
study. CS edited the manuscript. JL, DWD and LP conceived of the study,
participated in its design and coordination and edited the manuscript. All
authors read and approved the final manuscript.
Competing interests
YX, YZ, JL, and LP are inventors of this and related mouse models; however,
no royalties have been generated from this invention.
Received: 29 April 2011 Accepted: 26 October 2011
Published: 26 October 2011
References
1. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D,
Tsuchiya K, Yoshida M, Hashizume Y, Oda T: TDP-43 is a component of
ubiquitin-positive tau-negative inclusions in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res
Commun 2006, 351:602-611.
2. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT,
Bruce J, Schuck T, Grossman M, Clark CM, et al: Ubiquitinated TDP-43 in
frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Science 2006, 314:130-133.
3. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S,
Durnall JC, Williams KL, Buratti E, et al: TDP-43 mutations in familial and
sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
4. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande
Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al: TARDBP
mutations in individuals with sporadic and familial amyotrophic lateral
sclerosis. Nat Genet 2008, 40:572-574.
5. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D,
Hatanpaa KJ, White CL, Bigio EH, Caselli R, et al: TDP-43 A315T mutation in
familial motor neuron disease. Ann Neurol 2008, 63:535-538.
6. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ,
Kuntz K, Crook RJ, et al: Novel mutations in TARDBP (TDP-43) in patients with
familial amyotrophic lateral sclerosis. PLoS Genet 2008, 4:e1000193.
7. Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, Koyama A, Eguchi H,
Tsujino A, Ikeuchi T, Kakita A, et al: TDP-43 mutation in familial
amyotrophic lateral sclerosis. Ann Neurol 2008, 63:538-542.
8. Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE: Nuclear factor
TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9
skipping. EMBO J 2001, 20:1774-1784.
9. Buratti E, Baralle FE: Multiple roles of TDP-43 in gene expression, splicing
regulation, and human disease. Front Biosci 2008, 13:867-878.
10. Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V,
Ceuterick-de Groote C, Van Broeckhoven C, Kumar-Singh S: TDP-43
transgenic mice develop spastic paralysis and neuronal inclusions
characteristic of ALS and frontotemporal lobar degeneration. Proc Natl
Acad Sci USA 2010, 107:3858-3863.
11. Xu YF, Gendron TF, Zhang YJ, Lin WL, D’Alton S, Sheng H, Casey MC,
Tong J, Knight J, Yu X, et al: Wild-type human TDP-43 expression causes
TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and
early mortality in transgenic mice. J Neurosci 2010, 30:10851-10859.
12. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH: TDP-43 mutant
transgenic mice develop features of ALS and frontotemporal lobar
degeneration. Proc Natl Acad Sci USA 2009, 106:18809-18814.
13. Shan X, Chiang PM, Price DL, Wong PC: Altered distributions of Gemini of
coiled bodies and mitochondria in motor neurons of TDP-43 transgenic
mice. Proc Natl Acad Sci USA 2010, 107:16325-16330.
14. Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, Malunda J,
Xu Y, Winton MJ, Trojanowski JQ, Lee VM: Dysregulation of the ALS-
associated gene TDP-43 leads to neuronal death and degeneration in
mice. J Clin Invest 2011, 121:726-738.
15. Tsai KJ, Yang CH, Fang YH, Cho KH, Chien WL, Wang WT, Wu TW, Lin CP,
Fu WM, Shen CK: Elevated expression of TDP-43 in the forebrain of mice
is sufficient to cause neurological and pathological phenotypes
mimicking FTLD-U. J Exp Med 2010, 207:1661-1673.
16. Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, Julien JP:
Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal
lobar degeneration in transgenic mice produced with TDP-43 genomic
fragments. Brain 2011, 134:2610-2626.
17. Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J,
Copeland NG, Jenkins NA, Sisodia SS, Price DL: A vector for expressing
foreign genes in the brains and hearts of transgenic mice. Genet Anal
1996, 13:159-163.
18. Zhou H, Huang C, Chen H, Wang D, Landel CP, Xia PY, Bowser R, Liu YJ,
Xia XG: Transgenic rat model of neurodegeneration caused by mutation
in the TDP gene. PLoS Genet 2010, 6:e1000887.
19. Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M,
D’Ambrogio A, Tollervey J, Ule J, Baralle M, Buratti E, Baralle FE: TDP-43
regulates its mRNA levels through a negative feedback loop. EMBO J
2011, 30:277-288.
20. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY,
Ling SC, Sun E, Wancewicz E, Mazur C, et al: Long pre-mRNA depletion
and RNA missplicing contribute to neuronal vulnerability from loss of
TDP-43. Nat Neurosci 2011.
21. Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y, Dewey CM,
Roth FP, Herz J, Peng J, et al: Identification of neuronal RNA targets of
TDP-43-containing ribonucleoprotein complexes. J Biol Chem 2011,
286:1204-1215.
22. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J,
Hortobagyi T, Nishimura AL, Zupunski V, et al: Characterizing the RNA
targets and position-dependent splicing regulation by TDP-43. Nat
Neurosci 2011.
23. Gendron TF, Petrucelli L: The role of tau in neurodegeneration. Mol
Neurodegener 2009, 4:13.
24. Rothstein JD: Current hypotheses for the underlying biology of
amyotrophic lateral sclerosis. Ann Neurol 2009, 65(Suppl 1):S3-9.
25. De Vos KJ, Grierson AJ, Ackerley S, Miller CC: Role of axonal transport in
neurodegenerative diseases. Annu Rev Neurosci 2008, 31:151-173.
26. De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF,
Brownlees J, Ackerley S, Shaw PJ, McLoughlin DM, et al: Familial
amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal
transport to reduce axonal mitochondria content. Hum Mol Genet 2007,
16:2720-2728.
27. Tateno M, Kato S, Sakurai T, Nukina N, Takahashi R, Araki T: Mutant SOD1
impairs axonal transport of choline acetyltransferase and acetylcholine
release by sequestering KAP3. Hum Mol Genet 2009, 18:942-955.
28. Tanaka Y, Kanai Y, Okada Y, Nonaka S, Takeda S, Harada A, Hirokawa N:
Targeted disruption of mouse conventional kinesin heavy chain, kif5B,
results in abnormal perinuclear clustering of mitochondria. Cell 1998,
93:1147-1158.
29. Wakayama I: Morphometry of spinal motor neurons in amyotrophic
lateral sclerosis with special reference to chromatolysis and
intracytoplasmic inclusion bodies. Brain Res 1992, 586:12-18.
30. Strong MJ, Yang W, Strong WL, Leystra-Lantz C, Jaffe H, Pant HC: Tau
protein hyperphosphorylation in sporadic ALS with cognitive
impairment. Neurology 2006, 66:1770-1771.
31. Yang W, Sopper MM, Leystra-Lantz C, Strong MJ: Microtubule-associated
tau protein positive neuronal and glial inclusions in ALS. Neurology 2003,
61:1766-1773.
32. Zhang HX, Tanji K, Mori F, Wakabayashi K: Epitope mapping of 2E2-D3, a
monoclonal antibody directed against human TDP-43. Neurosci Lett 2008,
434:170-174.
doi:10.1186/1750-1326-6-73
Cite this article as: Xu et al.: Expression of mutant TDP-43 induces
neuronal dysfunction in transgenic mice. Molecular Neurodegeneration
2011 6:73.
Xu et al. Molecular Neurodegeneration 2011, 6:73
http://www.molecularneurodegeneration.com/content/6/1/73
Page 14 of 14